28Feb 2017

IDEAL WARFARIN DOSE ADJUSTMENT IN CARDIAC PATIENTS FOR SAFETY INR OUTCOME.

  • Clinical Pathology Department, Faculty of Medicine ? Sohag University, Egypt.
  • Internal Medicine Department, Faculty of Medicine ? Sohag University, Egypt.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Background: warfarin is effective for the primary and secondary prevention of both arterial and venous thromboembolic disorders. Its variable dose response and narrow time therapeutic range (TTR) mandate periodic monitoring of the international normalized ratio (INR). Aims: monitoring the dose change of warfarin therapy to adjust the INR in ideal values. Patients and methods: this study included 200 patients (103 males and 97 females) on oral anticoagulant, their age ranged from 17 to 66 years' old, classified into group 1(69) patients suffering from rheumatic heart disease (RHD), group 2(115) patients suffering from valve replacement and group 3(16) patients suffering from other cardiac conditions. They were subjected to full clinical examination and laboratory investigations including prothrombin time (PT), prothrombin concentration (PC) and INR, recording and follow up to the dose of oral anticoagulants, the control group included 28 healthy subjects matched in age and sex. Results: The target warfarin dose was 3-4 mg for RHD and 4-5mg for valve replacement; INR in the RHD versus valve replacement was 2 ∕ 3 (p = 0.001). PT in the RHD versus valve replacement was 16/23 sec. (p = <0.001). Conclusion: close monitoring of anticoagulant dose is required by blood testing (INR),during the initial stage of treatment, checking may be required daily.

  1. Schafer AI. Approach to the patient with bleeding and thrombosis. In: Goldman L, Ausiello D, eds. Cecil 23rd ed. Philadelphia, Pa: Saunders Elsevier; 2007: chap 178.
  2. Jordan?K.?Schaefer,?Robert?D,?McBane,?Waldemar?E.?Wysokinski. How to choose appropriate direct oral anticoagulant for patient with non-valvular atrial fibrillation. Ann Hematol (2016) 95(3):p 437 .-449 doi:10.1007/s00277-015-2566-x
  3. Zahir H, Brown KS, and Arndell AG. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation (2015) 131(1):82?90
  4. Piccini JP, Hellkamp AS, and Lokhnygina Y. Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. J Am Heart Assoc (2014) 3(2):e000521
  5. American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2014
  6. Streiff MB, Bockenstedt PL, Cataland SR, Chesney C, Eby C, Fanikos J, Fogerty AE, Gao S, Goldhaber SZ, Hassoun H, Hendrie P, Holmstrom B, Kuderer N, Lee JT, Millenson MM, Neff AT, Ortel TL, Siddigi T, Smith JL, Yee GC, Zakarija A, McMillan N, Naganuma M. Venous thromboembolic disease. J Natl Compr Canc Netw. 2013; 11(11):1402?29.
  7. Furie B and Furie BC. "Thrombus formation in vivo". J. Clin. Invest.2005. 115 (12): 3355?62.
  8. Krieck, Sven; G?rls, Helmar; Westerhausen, and Matthias."Mechanistic Elucidation of the Formation of the Inverse Ca (I) Sandwich Complex. Journal of the American Chemical Society 132 (35)
  9. Hylek EM, Evans-Molina C, Shea C, Henault LE and Regan S .Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation".Circulation 2007. 115 (21): 2689?96..)
  10. Shapiro SS. "Treating thrombosis in the 21st century". N. Engl. J. Med. 2003. 349 (18): 1762?4.
  11. Cerner Multum, Inc. Version: 14.01. Revision Date: 9/9/2011 3:52:58 PM.
  12. Wadelius M, Chen LY, Downes K, et al. "Common VKORC1 and GGCX polymorphisms associated with warfarin dose". Pharmacogenomics J 2005. 5 (4): 262?70
  13. Ratib S, Walker A J, Card TR and Grainge MJ. Risk of venous thromboembolism in hospitalized cancer patients in England a cohort study J Hematol Oncol (2016)9: 60. doi:10.1186/s13045-016-0291-0
  14. Majeed A, Hwang HG, and Connolly SJ Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation (2013)128:2325?2332
  15. Mo Y, and Yam FK. Recent advances in the development of specific antidotes for target-specific oral anticoagulants. Pharmacotherapy (2015), 35(2):198?207
  16. Hylek EM, Held C and Alexander JH. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): predictors, characteristics, and clinical outcomes. J Am Coll Cardiol (2014), 63(20):2141?2147
  17. Heidbuchel H, Verhamme P, Alings M. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Euro pace (2015), 17:1467?1507
  18. Lenzini PA, Grice GR and Milligan PE.Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. Journal of Thrombosis and Haemostasis 2008.6:1:8
  19. Rieder MJ, Reiner AP and Gage BF.Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med.2005. 352 (22): 2285?93.
  20. Walker AJ, West J, Card TR, Crooks C, Kirwan CC, Grainge MJ. Patients at highest risk of venous thromboembolism? A cohort study using English health care data. Blood. 2016;127(7):849?57
  21. Aston JL, Lodolce AE and Shapiro NL "Interaction between warfarin and cranberry juice". Pharmacotherapy, 2006.26(9):1314?9. doi:10.1592/phco.26.9.1314.
  22. Holbrook AM, Pereira JA and Labiris R. "Systematic overview of warfarin and its drug Warfarin and food interactions".? Intern. Med.2005. 165 (10): 1095?106
  23. Hirsh J, O'Donnell M, and Eikelboom JW. Beyond unfractionated heparin and warfarin: current and future advances". Circulation 2007.116 (5): 552?60. Doi: 10.1161.
  24. Mayo Foundation Members for Medical Education and Research, all rights reserved. Mayo Clinic, Embody Health, Enhance your life, and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research 2011

[Hasnaa A. Abo-Elwafa, Ahmed M. Boghdady, ErenySedek and Zeinab M. Mahmoud. (2017); IDEAL WARFARIN DOSE ADJUSTMENT IN CARDIAC PATIENTS FOR SAFETY INR OUTCOME. Int. J. of Adv. Res. 5 (Feb). 2569-2574] (ISSN 2320-5407). www.journalijar.com

Hasnaa A Abo-Elwafa
Assistant Prof. clinical pathology sohag university

DOI:

Article DOI: 10.21474/IJAR01/3442      
DOI URL: https://dx.doi.org/10.21474/IJAR01/3442

Download Full Paper

Download PDF No. of Downloads: 9 | No. of Views: 85